SERA (seraprognostics.com) Company Profit

Corporate emblem and logo of seraprognostics.com (SERA)

Sera Prognostics (SERA) specializes in reproductive health support and combating infertility. The asset's market dynamics on the GURU.Markets platform, where the indicator stands at -0.03, confirm the company's status as an authoritative developer of tests for newborn protection. High physician confidence is bolstered by the implementation of advanced proteomic research, which scales for the accurate prediction of preterm birth risks and possesses proven efficacy.

Sera Prognostics (SERA) Net Profit: for the period 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for Sera Prognostics, Inc. (SERA)

- stock value and consensus price forecast:
Market Price seraprognostics.com|SERA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Sera Prognostics, Inc.|SERA - Real Price to Acquire Entire Company
- book capitalization information:
Book Value per Share Sera Prognostics|SERA - Book Capitalization|Market Cap to Net Assets Ratio seraprognostics.com|SERA - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Sera Prognostics|SERA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Sera Prognostics Inc.|SERA - Company Debts|Debts to Book Value Sera Prognostics, Inc.|SERA - Company Long-Term Debt|Company Short-Term Indebtedness Sera Prognostics|Interim Coverage Ratio seraprognostics.com
- earnings and market multiples details:
SERA - Net Profit
Basic company analysis:SERA seraprognostics.com
Flagship merchandise of Sera Prognostics, Inc.

Analyzing the resilience of Sera Prognostics (SERA) to market downturns requires real-time monitoring of cash flows. Component shipments from Asia and customs duties directly impact the cost of goods sold for diagnostic tests. The company's current net result reflects profit dynamics in real time, offsetting the delays associated with standard reporting. This indicator measures the speed of margin reaction to rising costs. The stability of the curve confirms the business's margin of safety.

Main competitors

Company Net Income Natera Medical (NTRA)|HUMA (Humacyte, Inc.) - Net Profit